Beam Therapeutics, Inc. (BEAM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$25.18-6.15%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Manage operating losses: metric not reported.
Beam is advancing its gene editing portfolio with strong trial data. It aims to secure financing through 2029. Operating losses are being managed with some progress. The stock has gained 56.5% in the last 63 days, showing improving investor sentiment.
Beam remains unprofitable with expected EPS losses near -$4.5 in 2026. Revenue is expected to decline about 35% next year. The company faces risks from costly R&D and uncertain product approvals.
The market expects about -35% revenue growth and continued losses through 2026. Our fair value near $20 aligns with these expectations but assumes successful portfolio expansion and financing.
Breaks if: Failure to report meaningful progress or trial setbacks by end 2026
Breaks if: Operating losses worsen beyond -$110M per quarter over next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state reflects mixed management execution and a focus on advancing clinical programs, but recent results have been weak and risk is elevated.
The market currently prices BEAM at a premium compared to its peers, indicating high expectations despite the company's loss-making status. This premium suggests that investors are anticipating future growth, but the expectations gap is significant.
Management has prioritized advancing clinical programs, but recent financial performance has been weak. The probability of missing earnings estimates is notable, which adds to the uncertainty around future results.
The thesis hinges on the outcomes of clinical developments and the broader healthcare sector's performance. Key scenarios include potential earnings guidance cuts or positive momentum from sector leaders that could influence BEAM's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company advanced clinical development of BEAM-302 for AATD, which supports the thesis. However, the latest earnings miss raises concerns about financial performance, which weakens the read.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue decline exceeds -40% in 2026
Breaks if: Failure to secure or maintain financing covering expenses beyond 2027
Beam aims to secure sufficient financing to cover operating expenses and capital expenditures into 2029.
Over the next 1 to 3 years, BEAM faces a challenging environment with mixed signals from management and market conditions. Not investment advice.